with an indication) were on treatment. On discharge, 106 patients (44% of total surviving to discharge, 73% of those surviving with an indication for anticoagulation) were treated with oral anticoagulation. Of these patients, 89 (84%) were discharged on aspirin and an oral anticoagulant without clopidogrel. Only 122 (51% of total patients) were discharged on the regimen of aspirin and clopidogrel alone. Electronic supplementary material The online version of this article (doi:10.1007/s40119-015-0050-2) contains supplementary material, which is available to authorized users.
INTRODUCTION
Current guidelines call for lifelong aspirin (acetylsalicylic acid; ASA) with consideration of up to 6 months of clopidogrel following transcatheter aortic valve replacement (TAVR) [1] . Recently, small studies have questioned the necessity of dual antiplatelet therapy (DAPT) following the procedure [2] . Furthermore, many patients receiving TAVR have a pre-existing indication for oral anticoagulation (OAC), most commonly atrial fibrillation (AF) [3] and of these 77 (50%) were bridged with parental anticoagulation after the procedure.
Of the 145 patients with an indication for OAC who survived the initial hospitalization, 106 (73%) were discharged on an antithrombotic regimen that included an anticoagulant. Of the 16 surviving patients with new onset AF, 11 (69%) were newly started on OAC after TAVR.
In the total cohort there were 15 deaths, 13 strokes (10 ischemic, 2 hemorrhagic, and 1 unspecified) and 29 major bleeding events prior to discharge. The median time to stroke was 2 days post-procedure. Seven out of 13 patients with in-hospital stroke (5 ischemic) had longstanding AF. Of the 5 patients with [8] . This study showed a higher rate of triple therapy with 16% of total patients discharged on DAPT plus an anticoagulant [8] . Whether these regimens truly represent the optimal balance between bleeding and thrombosis following TAVR, particularly in patients at high risk for adverse events like those with AF, should be evaluated prospectively in future randomized trials. 
